los analistas de Citi mantuvieron una postura Neutral sobre las acciones de Amgen (NASDAQ:AMGN) con un precio objetivo de 295,00 dólares. El anuncio siguió a la aprobación por parte de la ...

Investing.com — El viernes, Piper Sandler reafirmó su confianza en las acciones de Amgen (NASDAQ:AMGN), manteniendo una calificación de Sobreponderación y un precio objetivo de 329 dólares.

TD Cowen analyst Yaron Werber maintained a Buy rating on Amgen (AMGN – Research Report) today and set a price target of $389.00. The company’s ...

In a report released yesterday, Courtney Breen from Bernstein maintained a Buy rating on Amgen (AMGN – Research Report), with a price target of ...

With a label expansion for Uplizna pushing the drug into an untouched rare disease market, Amgen is getting its money’s worth out of another drug from its $27.8 billion Horizon Therapeutics buy.

La presidenta de Farmaindustria y directora general de Amgen en España, Fina Lladós Canela, ha pedido "eliminar barreras" y "crear confianza" para aprovechar el potencial que ofrece la ...

Los científicos de deCODE Genetics, una filial de Amgen, revelan hoy en Nature Genetics asociaciones entre variantes raras de pérdida de función en dos genes y el trastorno bipolar REIKIAVIK ...

Las ingenieras Irene Villafañe (izquierda) y Maricarmen Szendrey (derecha), son, respectivamente, vicepresidenta de Manufactura de Productos Farmacéuticos y vicepresidenta de Calidad y ...

April 3 (Reuters) - The U.S. Food and Drug Administration has approved expanded use of Amgen's (AMGN.O), opens new tab drug, Uplizna, to help reduce the risk of flares in patients with a rare ...

Amgen’s $400 million eczema drug candidate has recorded two more phase 3 victories. The data drops provide more evidence that the Kyowa Kirin-partnered rocatinlimab improves outcomes in atopic ...

Amgen Inc.'s stock has surged 13% recently, likely due to promising developments with its obesity injection, MariTide, which offers unique benefits over current treatments. MariTide's dual ...